When considered with decreased proteasome function or defective autophagy, as is suspected to occur in AD and many other neurodegenerative conditions [95-98], Hsp90 inhibition could reduce the tau burden from an overburdened and dysregulated regulatory system. The gene discussed is MAPT; the disease is Alzheimer disease.